C. Baigent, A. Keech, and P. Kearney, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, vol.366, pp.1267-1278, 2005.

E. Mills, B. Rachlis, and P. Wu, Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments, Journal of the American College of Cardiology, vol.52, issue.22, pp.1769-1781, 2008.
DOI : 10.1016/j.jacc.2008.08.039

P. Kearney, L. Blackwell, and R. Collins, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, vol.371, pp.117-125, 2008.

P. Delahoy, D. Magliano, and K. Webb, The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis, Clinical Therapeutics, vol.31, issue.2, pp.236-244, 2009.
DOI : 10.1016/j.clinthera.2009.02.017

C. Cannon, B. Steinberg, and S. Murphy, Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy, Journal of the American College of Cardiology, vol.48, issue.3, pp.438-445, 2006.
DOI : 10.1016/j.jacc.2006.04.070

J. Afilalo, A. Majdan, and M. Eisenberg, Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials, Heart, vol.93, issue.8, pp.914-921, 2007.
DOI : 10.1136/hrt.2006.112508

S. Yusuf, S. Hawken, and S. Ounpuu, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, The Lancet, vol.364, issue.9438, pp.937-952, 2004.
DOI : 10.1016/S0140-6736(04)17018-9

M. Carr and J. Brunzell, Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.6, pp.2601-2607, 2004.
DOI : 10.1210/jc.2004-0432

A. Tenenbaum and E. Fisman, Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?, Cardiovascular Diabetology, vol.3, issue.1, p.10, 2004.
DOI : 10.1186/1475-2840-3-10

S. Grundy, J. Cleeman, and C. Merz, Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, vol.110, issue.2, pp.227-239, 2004.
DOI : 10.1161/01.CIR.0000133317.49796.0E

S. Smith, J. Allen, J. Blair, and S. , AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute, Circulation, vol.113, issue.19, pp.2363-2372, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.174516

J. Buse, H. Ginsberg, and G. Bakris, Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association, Circulation, vol.115, issue.1, pp.114-126, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.179294

I. Graham, D. Atar, and K. Borch-johnsen, European guidelines on cardiovascular disease prevention in clinical practice: Executive summary, Atherosclerosis, vol.194, issue.1, pp.2375-2414, 2007.
DOI : 10.1016/j.atherosclerosis.2007.08.024

B. Staels, M. Maes, and A. Zambon, Fibrates and future PPAR?? agonists in the treatment of cardiovascular disease, Nature Clinical Practice Cardiovascular Medicine, vol.99, issue.9, pp.542-553, 2008.
DOI : 10.1038/ncpcardio1278

V. Athyros, A. Kakafika, and K. Tziomalos, Pleiotropic Effects of Statins - Clinical Evidence, Current Pharmaceutical Design, vol.15, issue.5, pp.479-489, 2009.
DOI : 10.2174/138161209787315729

P. Ridker, E. Danielson, and F. Fonseca, Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, New England Journal of Medicine, vol.359, issue.21, pp.2195-2207, 2008.
DOI : 10.1056/NEJMoa0807646

J. Ansquer, C. Foucher, and P. Aubonnet, Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study, Current Pharmaceutical Design, vol.15, issue.5, pp.537-552, 2009.
DOI : 10.2174/138161209787315701

K. Koh, M. Quon, and S. Han, Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia, Journal of the American College of Cardiology, vol.45, issue.10, pp.1649-1653, 2005.
DOI : 10.1016/j.jacc.2005.02.052

J. Muhlestein, H. May, and J. Jensen, The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia, Journal of the American College of Cardiology, vol.48, issue.2, pp.396-401, 2006.
DOI : 10.1016/j.jacc.2006.05.009

R. Giraldez, R. Giugliano, and S. Mohanavelu, Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy, Journal of the American College of Cardiology, vol.52, issue.11, pp.914-920, 2008.
DOI : 10.1016/j.jacc.2008.05.046

C. Cannon, R. Giugliano, and M. Blazing, Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, American Heart Journal, vol.156, issue.5, pp.826-832, 2008.
DOI : 10.1016/j.ahj.2008.07.023

P. Ridker, E. Danielson, and F. Fonseca, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, The Lancet, vol.373, issue.9670, pp.1175-1182, 2009.
DOI : 10.1016/S0140-6736(09)60447-5

C. Ballantyne, A. Olsson, and T. Cook, Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S, Circulation, vol.104, issue.25, pp.3046-3051, 2001.
DOI : 10.1161/hc5001.100624

M. Cziraky, The impact of residual CVD risk in the managed care setting, Am J Manag Care, vol.15, pp.74-80, 2009.

T. Gordon, W. Castelli, and M. Hjortland, High density lipoprotein as a protective factor against coronary heart disease, The American Journal of Medicine, vol.62, issue.5, pp.707-714, 1977.
DOI : 10.1016/0002-9343(77)90874-9

P. Barter, A. Gotto, and J. Larosa, HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events, New England Journal of Medicine, vol.357, issue.13, pp.1301-1310, 2007.
DOI : 10.1056/NEJMoa064278

E. Degoma, N. Leeper, and P. Heidenreich, Clinical Significance of High-Density Lipoprotein Cholesterol in Patients With Low Low-Density Lipoprotein Cholesterol, Journal of the American College of Cardiology, vol.51, issue.1, pp.49-55, 2008.
DOI : 10.1016/j.jacc.2007.07.086

S. Nicholls, E. Tuzcu, and I. Sipahi, Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis, JAMA, vol.297, issue.5, pp.499-508, 2007.
DOI : 10.1001/jama.297.5.499

I. Goldenberg, M. Benderly, and U. Goldbourt, Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia, Journal of the American College of Cardiology, vol.51, issue.4, pp.459-465, 2008.
DOI : 10.1016/j.jacc.2007.09.048

I. Goldenberg, V. Boyko, and A. Tennenbaum, Long-term Benefit of High-Density Lipoprotein Cholesterol???Raising Therapy With Bezafibrate, Archives of Internal Medicine, vol.169, issue.5, pp.508-514, 2009.
DOI : 10.1001/archinternmed.2008.584

S. Bansal, J. Buring, and N. Rifai, Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women, JAMA, vol.298, issue.3, pp.309-316, 2007.
DOI : 10.1001/jama.298.3.309

P. Mcbride, Triglycerides and Risk for Coronary Heart Disease, JAMA, vol.298, issue.3, pp.336-338, 2007.
DOI : 10.1001/jama.298.3.336

N. Sarwar, J. Danesh, and G. Eiriksdottir, Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies, Circulation, vol.115, issue.4, pp.450-458, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.637793

M. Miller, C. Cannon, and S. Murphy, Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial, Journal of the American College of Cardiology, vol.51, issue.7, pp.724-730, 2008.
DOI : 10.1016/j.jacc.2007.10.038

R. Scott, O. Brien, R. Fulcher, and G. , Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Diabetes Care, vol.32, issue.3, pp.493-498, 2009.
DOI : 10.2337/dc08-1543

J. Robinson, S. Wang, and B. Smith, Meta-Analysis of the Relationship Between Non???High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk, Journal of the American College of Cardiology, vol.53, issue.4, pp.316-322, 2009.
DOI : 10.1016/j.jacc.2008.10.024

K. Ray, C. Cannon, and R. Cairns, Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT-TIMI 22, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.3, pp.424-430, 2009.
DOI : 10.1161/ATVBAHA.108.181735

J. Kastelein, W. Van-der-steeg, and I. Holme, Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment, Circulation, vol.117, issue.23, pp.3002-3009, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.713438

W. Cromwell, J. Otvos, and M. Keyes, LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study???Implications for LDL management, Journal of Clinical Lipidology, vol.1, issue.6, pp.583-592, 2009.
DOI : 10.1016/j.jacl.2007.10.001

A. Sniderman, Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice, Journal of Clinical Lipidology, vol.2, issue.1, pp.36-42, 2008.
DOI : 10.1016/j.jacl.2007.12.006

J. Contois, J. Mcconnell, and A. Sethi, Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Clinical Chemistry, vol.55, issue.3, pp.407-419, 2009.
DOI : 10.1373/clinchem.2008.118356

R. Rosenson, J. Otvos, and J. Hsia, Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled study, Diabetes Care, vol.32, issue.6, pp.1087-1091, 2009.
DOI : 10.2337/dc08-1681

M. Farnier, E. Roth, and B. Gil-extremera, Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia, American Heart Journal, vol.153, issue.2, pp.335-338, 2007.
DOI : 10.1016/j.ahj.2006.10.031

T. Filippatos and H. Milionis, Treatment of hyperlipidaemia with fenofibrate and related fibrates, Expert Opinion on Investigational Drugs, vol.51, issue.10, pp.1599-1614, 2008.
DOI : 10.1016/j.jacl.2008.04.023

R. Rosenson, D. Wolff, and A. Huskin, Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome, Diabetes Care, vol.30, issue.8, pp.1945-1951, 2007.
DOI : 10.2337/dc07-0015

D. Chan, G. Watts, and E. Ooi, Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.10
DOI : 10.1161/ATVBAHA.108.170530

J. Hogue, B. Lamarche, and Y. Deshaies, Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia, Metabolism, vol.57, issue.2, pp.246-254, 2008.
DOI : 10.1016/j.metabol.2007.09.008

G. Watts, P. Barrett, and J. J. , Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome, Diabetes, vol.52, issue.3, pp.803-811, 2003.
DOI : 10.2337/diabetes.52.3.803

S. Saha and R. Arora, Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus ??? A pooled meta-analysis of randomized placebo-controlled clinical trials, International Journal of Cardiology, vol.141, issue.2, 2009.
DOI : 10.1016/j.ijcard.2008.11.211

L. Tenkanen, M. Manttari, and P. Kovanen, Gemfibrozil in the Treatment of Dyslipidemia, Archives of Internal Medicine, vol.166, issue.7, pp.743-748, 2006.
DOI : 10.1001/archinte.166.7.743

H. Rubins, S. Robins, and D. Collins, Diabetes, Plasma Insulin, and Cardiovascular Disease, Archives of Internal Medicine, vol.162, issue.22, pp.2597-2604, 2002.
DOI : 10.1001/archinte.162.22.2597

A. Tenenbaum, M. Motro, and E. Fisman, Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome, Archives of Internal Medicine, vol.165, issue.10, pp.1154-1160, 2005.
DOI : 10.1001/archinte.165.10.1154

I. Goldenberg, M. Benderly, and R. Sidi, Relation of clinical benefit of raising highdensity lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial

V. Athyros, A. Papageorgiou, and V. Athyrou, Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia, Diabetes Care, vol.25, issue.7, pp.1198-1202, 2002.
DOI : 10.2337/diacare.25.7.1198

G. Vega, P. Ma, and N. Cater, Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome, The American Journal of Cardiology, vol.91, issue.8, pp.956-960, 2003.
DOI : 10.1016/S0002-9149(03)00111-5

S. Grundy, G. Vega, and Z. Yuan, Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial), The American Journal of Cardiology, vol.95, issue.4, pp.462-468, 2005.
DOI : 10.1016/j.amjcard.2004.10.012

H. May, J. Anderson, and R. Pearson, Comparison of Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Diabetic Patients With Mixed Dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study), The American Journal of Cardiology, vol.101, issue.4, pp.486-489, 2008.
DOI : 10.1016/j.amjcard.2007.09.095

S. Mohiuddin, C. Pepine, and M. Kelly, Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study, American Heart Journal, vol.157, issue.1, pp.195-203, 2009.
DOI : 10.1016/j.ahj.2008.08.027

A. Goldberg, H. Bays, and C. Ballantyne, Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia, The American Journal of Cardiology, vol.103, issue.4
DOI : 10.1016/j.amjcard.2008.10.025

P. Jones, M. Davidson, and M. Kashyap, Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study, Atherosclerosis, vol.204, issue.1, pp.208-215, 2009.
DOI : 10.1016/j.atherosclerosis.2008.09.027

J. Buse, J. Bigger, and R. Byington, Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods, The American Journal of Cardiology, vol.99, issue.12, pp.21-33, 2007.
DOI : 10.1016/j.amjcard.2007.03.003

@. Trial, ongoing for the lipid and blood pressure arms) documenting for the first time the benefits and risks of intensive glucose control, intensive blood pressure control, and the combination of fenofibrate and simvastatin in managing blood lipids in patients with T2DM

P. Jones and M. Davidson, Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin, The American Journal of Cardiology, vol.95, issue.1, pp.120-122, 2005.
DOI : 10.1016/j.amjcard.2004.08.076

T. Prueksaritanont, C. Tang, and Y. Qiu, Effects of Fibrates on Metabolism of Statins in Human Hepatocytes, Drug Metabolism and Disposition, vol.30, issue.11, pp.1280-1287, 2002.
DOI : 10.1124/dmd.30.11.1280

T. Zhu, W. Awni, and B. Hosmane, ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans, The Journal of Clinical Pharmacology, vol.54, issue.1, pp.63-71, 2009.
DOI : 10.1177/0091270008325671

S. Grundy, B. Hansen, S. Smith, and J. , Clinical Management of Metabolic Syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management, Circulation, vol.109, issue.4, pp.551-556, 2004.
DOI : 10.1161/01.CIR.0000112379.88385.67

4. Acronyms, Scandinavian Simvastatin Survival Study BIP : Bezafibrate Infarction Prevention PROVE-IT TIMI-22 : Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22